ArticlePreventive medicine reports2025
A multi-method spatial examination of factors associated with changes in geographic accessibility to buprenorphine providers in HEALing communities study states Kentucky, Massachusetts, and Ohio.
Article in Preventive medicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Objectives: Access to substance use treatment is critical to reduce the risk of opioid overdose. However, analyzing geographic accessibility using singular measures may provide imprecise estimates. Our objective was to examine changes in geographic accessibility to buprenorphine providers across three HEALing Communities Study (HCS) states, Kentucky, Massachusetts, and Ohio in the US, using multiple spatial analyses and determining whether disparities in access existed across geographic regions and sociodemographic indicators. Methods: We used buprenorphine provider data from the Drug Enforcement Administration database in January 2020 (reference point) and June 2022. We used four methods to examine changes in geographic accessibility to buprenorphine: 1) kernel density analysis; 2) change in rates analysis (at the county or municipality level); 3) minkowski distance (drive-time to the nearest provider); 4) enhanced 2-step floating catchment area (E2SFCA) and spatial regression analyses, controlling for HCS communities (Wave 1 or Wave 2) and other sociodemographic factors. Results: We identified an increase in geographic accessibility to buprenorphine across all three states. Improvements in accessibility were concentrated in areas that had higher reference point access. While our regression model of change in the E2SFCA accessibility index shows that Wave 1 communities in Kentucky had a higher increase in access compared to the state average increase, we were not able to establish consistent associations between HCS communities and changes in the E2SFCA index. Conclusion: Since geographic accessibility to buprenorphine treatment is critical, additional efforts are needed to improve access to buprenorphine providers in rural areas and areas with limited baseline access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.